Bruker Corporation (NASDAQ:BRKR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Bruker Corporation (NASDAQ:BRKR) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation, six have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $56.6429.

Several equities research analysts have recently commented on BRKR shares. Leerink Partners upped their price target on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Zacks Research upgraded shares of Bruker from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 4th. Finally, Stifel Nicolaus set a $50.00 target price on shares of Bruker in a research note on Wednesday, August 5th.

Bruker Stock Performance

NASDAQ BRKR opened at $56.98 on Thursday. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. Bruker has a 52-week low of $28.53 and a 52-week high of $65.30. The business’s 50-day moving average price is $58.67 and its 200 day moving average price is $47.61. The firm has a market cap of $8.68 billion, a P/E ratio of -81.40, a P/E/G ratio of 1.82 and a beta of 1.28.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.11. The firm had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities research analysts expect that Bruker will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 21st. Bruker’s dividend payout ratio is currently -28.57%.

Institutional Investors Weigh In On Bruker

A number of institutional investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC acquired a new stake in Bruker in the fourth quarter valued at $26,000. Allworth Financial LP grew its stake in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the last quarter. Essential Partners LLC bought a new position in shares of Bruker in the first quarter valued at $36,000. Global Retirement Partners LLC acquired a new stake in shares of Bruker during the second quarter worth $38,000. Finally, Parallel Advisors LLC lifted its stake in Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after buying an additional 479 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.